Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

To be part of this study, you must have been recently diagnosed with solitary bone plasmacytoma and have finished your radiotherapy treatment within the last 28 days. You need to be at least 18 years old and in reasonably good health, able to manage everyday activities without too much trouble.

There are also some reasons why you might not be able to join. For example, if your cancer has spread to many places, or if it's outside your bones, this study wouldn't be right for you. You also couldn't take part if you have certain other conditions, like severe liver or kidney problems, or uncontrolled diabetes. If you're pregnant or breastfeeding, or have a high risk of blood clots, you also wouldn't be able to join. The study team will check all these details carefully with you and your doctor.

If you decide to take part, you'll be randomly assigned to one of two groups: one group will receive the medicines lenalidomide and dexamethasone after their radiotherapy, and the other group will only continue with standard follow-up after radiotherapy. You'll have regular hospital visits, likely including blood tests, physical examinations, and possibly scans, to check how you're responding to treatment and monitor your health. The study team will provide you with the medications if you are in that group and explain exactly how to take them. You will be closely followed for a period of time to see how your condition progresses.

For women, if you are able to become pregnant, you'll need to agree to use effective contraception as part of a pregnancy prevention program because the study medicines can be harmful to a developing baby. The total duration of your participation, including follow-up, will be clearly explained by the study team.